Answers are grounded in this paper and cite their sources.
Post-transplantation cyclophosphamide (PTCy)-based prophylaxis has become one of the most widely used strategies to prevent graft-versus-host disease (GVHD), particularly after HLA-haploidentical hematopoietic cell transplantation (HCT). Well-tolerated GVHD prophylaxis regimens beyond PTCy are needed, because adverse events associated with Cy administration, such as cardiac toxicity, remain a safety concern. Costimulation blockade using abatacept (ABA) is an established complementary strategy to improve GVHD prevention without a calcineurin inhibitor. Here, we investigated venetoclax (VEN), a selective B-cell leukemia/lymphoma 2 (BCL-2) inhibitor, as a candidate partner with ABA to prevent GVHD. In a murine MHC-haploidentical HCT model, we demonstrate that prevention of GVHD with a combination of short-term VEN and CD28 costimulation blockade using ABA (VEN+ABA) was comparable to that with Cy+ABA and superior to that with Cy monotherapy, while maintaining GVL effects. Flow cytometry analysis revealed a higher regulatory T (Treg)/conventional T (Tcon) ratio with the VEN+ABA combination compared to Cy+ABA. Using donor CD8+ alloreactive TCR-transgenic T cells, we show that the VEN+ABA combination produced a prominent cleaved caspase-3 signature only in allo-activated T cells, and cells from the spleen at day 9 after HCT with VEN+ABA did not respond after ex vivo CD3/CD28 stimulation. Collectively, our study supports a VEN+ABA GVHD prophylaxis strategy associated with preferential apoptosis of alloreactive T cells while preserving GVL activity to replace alkylator-based prophylaxis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: